[
  {
    "trial_name": "MK-1026-011",
    "clinical_trial_number": "MK-1026-011",
    "disease_category": "CLL",
    "inclusion_criteria_simple": "Untreated",
    "mechanism_of_action": "BTK inhibitor",
    "inclusion_criteria_detailed": "Age: ≥20 years\nPhase: III",
    "study_design": "III",
    "study_drug": "Nemtabrutinib",
    "control_arm": "ibrutina/acalatinib",
    "expected_enrollment": 7,
    "already_enrolled": 6,
    "study_nurse": "李佳玲",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "BGB-16673-303",
    "clinical_trial_number": "BGB-16673-303",
    "disease_category": "CLL",
    "inclusion_criteria_simple": "Relapsed/Refractory CLL/SLL \n(Exposed to Covalent BTK Inhibitors)",
    "mechanism_of_action": "BTK-targeting chimeric degradation activation compound (CDAC)",
    "inclusion_criteria_detailed": "Age: ≥18 years\nPhase: III",
    "study_design": "III",
    "study_drug": "Catadegbrutinib (BGB-16673)",
    "control_arm": "BR / \nhigh-dose methylprednisolone\n+ rituximab (HDMP+R),",
    "expected_enrollment": 4,
    "already_enrolled": 1,
    "study_nurse": "李佳玲",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "20190360",
    "clinical_trial_number": "20190360",
    "disease_category": "ALL",
    "inclusion_criteria_simple": "untreated",
    "mechanism_of_action": "anti-CD19",
    "inclusion_criteria_detailed": "Age: ≥18 years\nPhase: III",
    "study_design": "III",
    "study_drug": "Blinatumomab",
    "control_arm": "GMALL\nHyper-CVAD",
    "expected_enrollment": 4,
    "already_enrolled": 3,
    "study_nurse": "李佳玲",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "D7405C00001",
    "clinical_trial_number": "D7405C00001",
    "disease_category": "ALL",
    "inclusion_criteria_simple": "1.≥2 prior Tx\n2. CD19(+)\n3. PH(+)->至少兩線TKI failure or replase\n4. PH(-)->至少兩線systemic therapy failure",
    "mechanism_of_action": "anti-CD19/CD3",
    "inclusion_criteria_detailed": "Age: 1. ≥12 years\n2. CD19+\nPhase: I/ II",
    "study_design": "I/ II",
    "study_drug": "AZD0486",
    "control_arm": "",
    "expected_enrollment": 3,
    "already_enrolled": 0,
    "study_nurse": "吳軒綾",
    "contact_tel": "3998",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "DSP-5336-101",
    "clinical_trial_number": "DSP-5336-101",
    "disease_category": "ALL",
    "inclusion_criteria_simple": "4 cycle HMA/ LDAC or 2 cycle combination therapy failure for refractory group",
    "mechanism_of_action": "Menin inhibitor",
    "inclusion_criteria_detailed": "Age: ≥18 years\nPhase: I/ II",
    "study_design": "I/ II",
    "study_drug": "DSP-5336",
    "control_arm": "",
    "expected_enrollment": 3,
    "already_enrolled": 0,
    "study_nurse": "鄭采涵",
    "contact_tel": "3974",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "75276617ALE1001",
    "clinical_trial_number": "75276617ALE1001",
    "disease_category": "AML-MDS",
    "inclusion_criteria_simple": "Cohort A1: KMT2A-r AML\nCohort A2: NPM1m AML",
    "mechanism_of_action": "Menin-KMT2A (MLL1) inhibitor",
    "inclusion_criteria_detailed": "Age: ≥18 years\nPhase: II",
    "study_design": "II",
    "study_drug": "Bleximenib",
    "control_arm": "",
    "expected_enrollment": 2,
    "already_enrolled": 0,
    "study_nurse": "李佳玲",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "AC220-168",
    "clinical_trial_number": "AC220-168",
    "disease_category": "AML-MDS",
    "inclusion_criteria_simple": "Untreated & FLT3-ITD(-)",
    "mechanism_of_action": "class III receptor tyrosine kinases",
    "inclusion_criteria_detailed": "Age: ≥18 years\nPhase: III",
    "study_design": "III",
    "study_drug": "Quizartinib/ Placebo",
    "control_arm": "",
    "expected_enrollment": 4,
    "already_enrolled": 1,
    "study_nurse": "李佳玲",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "KER-050-D301",
    "clinical_trial_number": "KER-050-D301",
    "disease_category": "AML-MDS",
    "inclusion_criteria_simple": "very low-, low-, intermediate risk MDS",
    "mechanism_of_action": "tgf-β ligand",
    "inclusion_criteria_detailed": "Age: ≥18 years\nPhase: III",
    "study_design": "III",
    "study_drug": "Elritercept/ placebo",
    "control_arm": "",
    "expected_enrollment": 0,
    "already_enrolled": 0,
    "study_nurse": "李佳玲",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "ZE46-0134-0002-US",
    "clinical_trial_number": "ZE46-0134-0002-US",
    "disease_category": "AML-MDS",
    "inclusion_criteria_simple": "Group 1: FLT3 ITD/TDK mutation\nGroup 2: Spliceosome Mutation (SF3B1, SRSF2, U2AF1, ZRSR2)",
    "mechanism_of_action": "FLT3 inhibitors",
    "inclusion_criteria_detailed": "Age: ≥18 years\nPhase: I",
    "study_design": "I",
    "study_drug": "ZE46-0134",
    "control_arm": "",
    "expected_enrollment": 0,
    "already_enrolled": 0,
    "study_nurse": "李佳玲",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "R1979-ONC-2210\n(Olympia-5)",
    "clinical_trial_number": "R1979-ONC-2210\n(Olympia-5)",
    "disease_category": "Lymphoma",
    "inclusion_criteria_simple": "1.R/R\n2.≥1 prior Tx",
    "mechanism_of_action": "CD20+CD3 bispecific Ab",
    "inclusion_criteria_detailed": "Age: \nPhase: III",
    "study_design": "III",
    "study_drug": "Odronextamab+ Lenalidomide",
    "control_arm": "R2",
    "expected_enrollment": 3,
    "already_enrolled": 0,
    "study_nurse": "溫上容",
    "contact_tel": "3998",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "R1979-HM-2299\n(Olympia-4)",
    "clinical_trial_number": "R1979-HM-2299\n(Olympia-4)",
    "disease_category": "Lymphoma",
    "inclusion_criteria_simple": "1. DLBCL(de novo or transformed indolent NHL, high-grade B with MYC+BCL2 ± BCL6\n2. r/r within 12m from 1st treatment",
    "mechanism_of_action": "CD20+CD3 bispecific Ab",
    "inclusion_criteria_detailed": "Age: \nPhase: III",
    "study_design": "III",
    "study_drug": "Odronextamab",
    "control_arm": "R-ICE\nR-DHAP\nR-GDP",
    "expected_enrollment": 3,
    "already_enrolled": 1,
    "study_nurse": "劉璟穎",
    "contact_tel": "6452",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "ACE1831-001",
    "clinical_trial_number": "ACE1831-001",
    "disease_category": "Lymphoma",
    "inclusion_criteria_simple": "R/R",
    "mechanism_of_action": "ACC(CAR-T)",
    "inclusion_criteria_detailed": "Age: \nPhase: I b/ II",
    "study_design": "I b/ II",
    "study_drug": "ACE1831",
    "control_arm": "",
    "expected_enrollment": 4,
    "already_enrolled": 2,
    "study_nurse": "鄭采涵",
    "contact_tel": "3974",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "M22-003",
    "clinical_trial_number": "M22-003",
    "disease_category": "Lymphoma",
    "inclusion_criteria_simple": "newly diagnosed + stage, III or IV disease, or stage II with bulky disease",
    "mechanism_of_action": "CD20+CD3 bispecific Ab",
    "inclusion_criteria_detailed": "Age: \nPhase: III",
    "study_design": "III",
    "study_drug": "Epcoritamab+ R2",
    "control_arm": "Arm B: G-CHOP/ R-CHOP/ BR\nArm C: R2",
    "expected_enrollment": 5,
    "already_enrolled": 4,
    "study_nurse": "鄭采涵",
    "contact_tel": "3974",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "EZH-302",
    "clinical_trial_number": "EZH-302",
    "disease_category": "Lymphoma",
    "inclusion_criteria_simple": "≥1 prior Tx",
    "mechanism_of_action": "EZH 2 innibitor",
    "inclusion_criteria_detailed": "Age: \nPhase: III",
    "study_design": "III",
    "study_drug": "Tazemetostat+ R2",
    "control_arm": "placebo +R2",
    "expected_enrollment": 6,
    "already_enrolled": 6,
    "study_nurse": "鄭采涵",
    "contact_tel": "3974",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "D7400C00006",
    "clinical_trial_number": "D7400C00006",
    "disease_category": "Lymphoma",
    "inclusion_criteria_simple": "1. R/R \n2. ≥2 prior Tx",
    "mechanism_of_action": "CD19+CD3 bispecific Ab",
    "inclusion_criteria_detailed": "Age: \nPhase: I",
    "study_design": "I",
    "study_drug": "AZD0486(TNB-486)",
    "control_arm": "",
    "expected_enrollment": 5,
    "already_enrolled": 3,
    "study_nurse": "鄭采涵",
    "contact_tel": "3974",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "DR-01-ONC-001",
    "clinical_trial_number": "DR-01-ONC-001",
    "disease_category": "Lymphoma",
    "inclusion_criteria_simple": "≥1 prior Tx",
    "mechanism_of_action": "human IgG1 antibody against CD94,",
    "inclusion_criteria_detailed": "Age: \nPhase: I/II",
    "study_design": "I/II",
    "study_drug": "DR-01",
    "control_arm": "",
    "expected_enrollment": 2,
    "already_enrolled": 2,
    "study_nurse": "李佳玲",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "DZ2022J0004",
    "clinical_trial_number": "DZ2022J0004",
    "disease_category": "Lymphoma",
    "inclusion_criteria_simple": "≥1 prior Tx",
    "mechanism_of_action": "JAK 1",
    "inclusion_criteria_detailed": "Age: \nPhase: III",
    "study_design": "III",
    "study_drug": "Golidicitinib",
    "control_arm": "Pralatrexate(缺藥)\nBelinostat\nGemcitabine\nChidamide",
    "expected_enrollment": 4,
    "already_enrolled": 3,
    "study_nurse": "李佳玲",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "D7404C00001\n(SOUNDTRACK-B)",
    "clinical_trial_number": "D7404C00001\n(SOUNDTRACK-B)",
    "disease_category": "Lymphoma",
    "inclusion_criteria_simple": "1. R/R \n2. ≥2 prior Tx",
    "mechanism_of_action": "CD19+CD3 bispecific Ab",
    "inclusion_criteria_detailed": "Age: \nPhase: II",
    "study_design": "II",
    "study_drug": "AZD0486",
    "control_arm": "Single-Arm (-)",
    "expected_enrollment": 0,
    "already_enrolled": 2,
    "study_nurse": "李佳玲",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "D7401C00001",
    "clinical_trial_number": "D7401C00001",
    "disease_category": "Lymphoma",
    "inclusion_criteria_simple": "newly diagnosed + stage, III or IV disease, or stage II with bulky disease",
    "mechanism_of_action": "CD19+CD3 bispecific Ab",
    "inclusion_criteria_detailed": "Age: \nPhase: III",
    "study_design": "III",
    "study_drug": "AZD0486",
    "control_arm": "AZD0486+Rituximab",
    "expected_enrollment": 10,
    "already_enrolled": 1,
    "study_nurse": "吳宜真",
    "contact_tel": "3974",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "M22-132\n(名額需問slot)",
    "clinical_trial_number": "M22-132\n(名額需問slot)",
    "disease_category": "Lymphoma",
    "inclusion_criteria_simple": "Newly diagnosed",
    "mechanism_of_action": "CD20+CD3 bispecific Ab",
    "inclusion_criteria_detailed": "Age: \nPhase: I b/ II",
    "study_design": "I b/ II",
    "study_drug": "Epcoritamab + Polatuzumab +RCHP",
    "control_arm": "",
    "expected_enrollment": 0,
    "already_enrolled": 2,
    "study_nurse": "李佳玲",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "R3918-PNH-2021",
    "clinical_trial_number": "R3918-PNH-2021",
    "disease_category": "PNH",
    "inclusion_criteria_simple": "Untreat or \nEculizumab stop over 3 m or\nRavulizumab stop over 6 m",
    "mechanism_of_action": "C5 inhibitor",
    "inclusion_criteria_detailed": "Age: \nPhase: III",
    "study_design": "III",
    "study_drug": "C5 inhibitor",
    "control_arm": "Eculizumab",
    "expected_enrollment": 0,
    "already_enrolled": 0,
    "study_nurse": "李佳玲",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "MK3543-007",
    "clinical_trial_number": "MK3543-007",
    "disease_category": "MPN",
    "inclusion_criteria_simple": "untreat",
    "mechanism_of_action": "LSD1",
    "inclusion_criteria_detailed": "Age: \nPhase: III",
    "study_design": "III",
    "study_drug": "MK3543/Hydroxyurea(placebo)",
    "control_arm": "Hydroxyurea(placebo)/MK3543",
    "expected_enrollment": 0,
    "already_enrolled": 0,
    "study_nurse": "李佳玲",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "KRT-232-115",
    "clinical_trial_number": "KRT-232-115",
    "disease_category": "MPN",
    "inclusion_criteria_simple": "JAK inhibitor naive",
    "mechanism_of_action": "MDM2",
    "inclusion_criteria_detailed": "Age: \nPhase: III",
    "study_design": "III",
    "study_drug": "Navtemadlin + Ruxolitinib",
    "control_arm": "Navtemadlin(placebo) + Ruxolitinib",
    "expected_enrollment": 0,
    "already_enrolled": 0,
    "study_nurse": "李佳玲",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "CT-P44 3.1",
    "clinical_trial_number": "CT-P44 3.1",
    "disease_category": "MM",
    "inclusion_criteria_simple": "≥1 prior Tx(Including Lenalidomide )",
    "mechanism_of_action": "CD38+",
    "inclusion_criteria_detailed": "Age: \nPhase: III",
    "study_design": "III",
    "study_drug": "CT-P44+Lena+Dexa",
    "control_arm": "DRd",
    "expected_enrollment": 10,
    "already_enrolled": 0,
    "study_nurse": "溫上容",
    "contact_tel": "3998",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "IM048-022\n(EXCALIBER-Maint))",
    "clinical_trial_number": "IM048-022\n(EXCALIBER-Maint))",
    "disease_category": "MM",
    "inclusion_criteria_simple": "after ASCT with NDMM",
    "mechanism_of_action": "CUL4-CRBN E3-Bite",
    "inclusion_criteria_detailed": "Age: \nPhase: III",
    "study_design": "III",
    "study_drug": "Iberdomide",
    "control_arm": "Lenalidomide",
    "expected_enrollment": 7,
    "already_enrolled": 2,
    "study_nurse": "曾睦捷",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "DREAMM-10(214828)",
    "clinical_trial_number": "DREAMM-10(214828)",
    "disease_category": "MM",
    "inclusion_criteria_simple": "1. Newly diagnosed MM\n2. ineligible for ASCT",
    "mechanism_of_action": "BCMA",
    "inclusion_criteria_detailed": "Age: \nPhase: III",
    "study_design": "III",
    "study_drug": "belantamab mafodotin+Lena+Dexa",
    "control_arm": "DRd",
    "expected_enrollment": 5,
    "already_enrolled": 3,
    "study_nurse": "鄭采涵",
    "contact_tel": "3974",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "C1071005",
    "clinical_trial_number": "C1071005",
    "disease_category": "MM",
    "inclusion_criteria_simple": "≥2 prior Tx (Including Lenalidomide and Proteasome Inhibitor )",
    "mechanism_of_action": "BCMA-Bite",
    "inclusion_criteria_detailed": "Age: \nPhase: III",
    "study_design": "III",
    "study_drug": "1. Elranatamab\n2. Elranatamab+Dara",
    "control_arm": "",
    "expected_enrollment": 10,
    "already_enrolled": 3,
    "study_nurse": "曾睦捷",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  },
  {
    "trial_name": "87562761MMY1001",
    "clinical_trial_number": "87562761MMY1001",
    "disease_category": "MM",
    "inclusion_criteria_simple": "RRMM",
    "mechanism_of_action": "GPRC5D",
    "inclusion_criteria_detailed": "Age: \nPhase: I",
    "study_design": "I",
    "study_drug": "JNJ-87562761",
    "control_arm": "",
    "expected_enrollment": 1,
    "already_enrolled": 1,
    "study_nurse": "曾睦捷",
    "contact_tel": "4620",
    "pi": "Unknown",
    "status": "Recruiting",
    "sponsor": "Unknown"
  }
]